Ethnic minority groups less informed about cancer symptoms
the ONA take:
According to new findings presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, United Kingdom, ethnic minorities in England were less informed about cancer symptoms and were less likely to see a doctor when they thought they had a possibly serious symptom.
Researchers at King's College London in London, United Kingdom, analyzed about 50,000 responses from the Cancer Research UK Cancer Awareness Measure, a national population-based survey to investigate levels of cancer awareness. Researchers found that people with a black ethnic background were half as likely as white people to identify unexplained bleeding as a possible cancer symptom.
People of South Asian descent were a one-fourth as likely as white people to identify an explained lump as a possible cancer symptom. In addition, people with South Asian backgrounds were more likely to report embarrassment and low confidence to discuss their symptoms with their doctor, while white people were more concerned about wasting the physician's time.
The findings suggest that more public awareness is needed to help people identify cancer symptoms earlier in disease progression and that people need to be encouraged to discuss unexplained changes in their body with their physician.
Ethnic minorities less informed about cancer symptoms and less likely to see a doctor.
Ethnic minorities in England are less aware of cancer symptoms and more likely to say they wouldn't see the doctor, even when they have a symptom that they think might be serious, according to research being presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
Researchers looked at nearly 50,000 responses to the Cancer Research UK Cancer Awareness Measure* from people across England. They found that ethnic minority groups were consistently less aware of cancer symptoms.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|